STAT3途径有助于β-HCH干扰抗癌类氨酸激酶抑制剂
Sara Fiorini1, Elisabetta Rubini2, Monia Perugini3
1Department of Biochemical Science "A. Rossi Fanelli", Faculty of Pharmacy and Medicine, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
International journal of molecular sciences
|June 19, 2024
概括
长时间接触有机农药,如β-hexachlorocyclohexane (β-HCH) 可以降低癌症药物的有效性. 抑制STAT3信号恢复了抗癌药物的有效性,突出了环境污染物.
科学领域:
- 环境毒理学环境毒理学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 有机化农药 (OCP) 是一种持久性污染物.
- 林丹合成的副产品β-hexachlorocyclohexane (β-HCH) 是一个广泛的OCP.
- β-HCH与化学抵抗具有相同的细胞机制,包括STAT3通路的激活.
研究的目的:
- 调查β-HCH暴露对抗癌药物疗效的影响.
- 阐明信号传感器和转录3激活器 (STAT3) 在β-HCH诱导的化学抵抗中的作用.
- 评估STAT3抑制恢复药物疗效的潜力.
主要方法:
- 用β-HCH和氨酸激酶抑制剂 (TKI) 或STAT3抑制剂治疗乳腺,肺,前列腺和肝细胞癌细胞系.
- 分析使用生命力,免疫阻塞,伤口愈合和殖民地形成试验.
主要成果:
- 暴露于β-HCH显著降低了TKI的有效性.
- STAT3信号传递是β-HCH对药物疗效的影响的核心.
- 抑制STAT3活性恢复了抗癌药物的疗效.
结论:
- 暴露于β-HCH会通过激活STAT3.3影响TKI的有效性.
- STAT3抑制是克服β-HCH诱导化学抵抗的可行策略.
- 强调有必要解决环境污染物暴露及其对癌症治疗结果的影响.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


